Friday, 4 September 2026European Markets

NR21 Stock Is 10% Down So Far Today

Loading stream...

(vianews) - shares of nr21 (cac 40: nr21.pa) slid 10% to €81.00 at 13:06 est on wednesday, after five sequential sessions in a row of losses. cac 40 is falling 0.97% to €7,237.93, after three consecutive sessions in a row of losses. this seems, up until now, a somewhat negative trend exchanging session today.

about nr21

nr21 société anonyme does not have significant operations. previously, it was involved in design and distribution of underwear and indoor clothing for men, women, and children. the company is based in paris, france.

volatility

nr21's last week, last month's, and last quarter's current intraday variation average was a negative 11.11%, a negative 9.06%, and a positive 6.02%.

nr21's highest amplitude of average volatility was 11.11% (last week), 9.06% (last month), and 6.02% (last quarter).

volume

today's last reported volume for nr21 is 4 which is 300% above its average volume of 1.

more news about nr21 (nr21.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Funding Surge: Capital Floods Fintech, Foundation Models, and Autonomous Systems
A concentrated burst of AI-linked funding on 2026-08-28 pushed well over $1.5B into companies spanning fraud/identity fintech (Socure, which also acquired Fravity), foundation models (Stability AI), AI agents and enterprise tooling (Instinct, Generalist AI, Emerald AI, Owner), and AI-adjacent autonomous/aerospace ventures (Gatik, Regent Craft). The breadth and simultaneity of these rounds signal that investor appetite for AI is not concentrated in a single vertical but is broadening into applied and infrastructure-adjacent domains, with consolidation (Socure-Fravity) beginning alongside fresh capital formation.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,269 source documents archived
Query this data → isubstrate.com